Figure: The innovative system offers a faster way to diagnose blood -transmitted infections (Melio’s polite)
Neonatal sepsis is a potentially deadly disease caused by infection of blood inflow in newborns within 28 days. Because your immune system is immature, newborns are particularly vulnerable to infections. It is estimated that 2.5 million newborns or children in the first month of life die every year during sepsis, with the greatest impact on countries with low and medium incomes. Because neonatal sepsis progress rapidly, it requires immediate treatment with intravenous and antibiotic fluids. The risk of death due to neonatal sepsis increases by 7.6 % per hour that the treatment is delayed. A new diagnosis is now developing that combines molecular and microfluid technologies to quickly detect pathogens and resistance to the drug directly in the blood in a few hours.
Melio (Santa Clara, Ca, USA) creates a platform without cultivating to identify blood torrent infections, including neonatal sepsis. Through the integration of advanced molecular and microfluid technologies, Melio’s diagnoses require culture and have been for several days. If you succeed, the diagnostic ability to analyze small volumes of blood with high negative predictive value would deal with a critical gap in the attention of neonatal sepsis. Medical care providers would allow this timely and specific antimicrobial decisions that could save lives, reduce unnecessary use of antibiotics and prevent adverse effects or hospitalization during an early phase of life. Melio received $ 3.5 million from the biopharmaceutical accelerator to combat bacteria resistant to antibiotics (Carb-X, Boston, MA, USA) to develop and perform a technical plan for its platform without cultivation.
‘The tests of the identification of the current pathogen threaten the sensitivity or amplitude of detected pathogens. A truly disturbing approach is needed to violate this balance and offered the “Holy Grail” for blood torrent infections, “said Mrida Sunha, doctorate, founder and CEO of Melio. “Melio is tirelessly working to re -evaluate these technical challenges with innovative thinking, designing innovative ways to question and identify pathogens that provide comprehensive evidence of known pathogens, while allowing detection or new threats to be detected. We are excited to join the Carb-X ecosystem, which connects us with a network of clinical experts and politics, promotes cooperation, learns and significantly speeds up our path to commercialization. ”
“Melio technology that uses direct blood insulation through acoustic technology followed by the identification of the fusion curve, if successfully, was a great progress to detect neonatal sepsis, syndrome that increases the probability of mortality how much treatment is delayed, would be postponed, postponed, postponed Treatment, treatment, treatment, treatment would be delayed, increasing how much treatment is delayed. “Erin Duffy, PhD, Carb-X research and development director said. “We hope to work with Melius to better understand his technology and speed up this diagnosis so that you can address medical staff and patients faster.”
Related links:
Melio
Carb-x
(Tagstotranslate) Reports of Clinical Lip of the Day
